Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rocket Pharmaceuticals (RCKT) EBIT Margin: 2016-2025

Historic EBIT Margin for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Sep 2025 value amounting to 11,045.88%.

  • Rocket Pharmaceuticals' EBIT Margin fell 369383.00% to 11,045.88% in Q3 2025 from the same period last year, while for Sep 2025 it was 13,245.80%, marking a year-over-year decrease of 129430.00%. This contributed to the annual value of 14,485.95% for FY2024, which is 63747.00% up from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' EBIT Margin stood at 11,045.88%, which was down 26.57% from 15,042.07% recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' EBIT Margin ranged from a high of 15,650.11% in Q2 2024 and a low of 2,268.48% during Q1 2021.
  • In the last 3 years, Rocket Pharmaceuticals' EBIT Margin had a median value of 13,950.75% in 2023 and averaged 13,915.80%.
  • Per our database at Business Quant, Rocket Pharmaceuticals' EBIT Margin surged by 1,224,585bps in 2021 and then tumbled by 369,383bps in 2025.
  • Rocket Pharmaceuticals' EBIT Margin (Quarterly) stood at 9,575.16% in 2021, then surged by 521,756bps to 14,792.72% in 2022, then plummeted by 132,910bps to 13,463.62% in 2023, then tumbled by 20,907bps to 13,254.55% in 2024, then plummeted by 369,383bps to 11,045.88% in 2025.
  • Its EBIT Margin stands at 11,045.88% for Q3 2025, versus 15,042.07% for Q2 2025 and 13,641.53% for Q1 2025.